Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, talks to MPR about the potential of psilocybin as a therapy for major depressive disorder.
MamaLift Plus is intended as an adjunct to clinician-managed outpatient care to provide neurobehavioral interventions to patients 22 years of age and older with mild to moderate PPD.
Association seen between green space and fewer internalizing symptoms
The double-blind, phase 3 study included 2 groups of patients, those who were not on positive airway pressure therapy and those who were.
Although most effective for symptoms, medications are also tied to adverse effects.
The phase 3 study evaluated the efficacy and safety of lumateperone as an adjunctive treatment to antidepressants in 485 patients with MDD.
A record high of 323 different meds were in short supply during the first quarter of 2024,
Single low-dose esketamine reduces depressive episodes at 42 days postpartum for mothers with prenatal depression
Improvements seen in cognition, cholesterol, blood sugar, and C-reactive protein
The treatment is delivered for a period of 30 minutes before bed.
The table below is a review of notable updates that occurred in March 2024 for investigational products in development.
Benefits seen across anthropometric, metabolic, biomarker, and psychiatric outcomes
First prescription smartphone app is approved for major depressive disorder; Novel blood test to detect TBI; Zevtera has been approved for bloodstream infections; The Mpox vaccine is now commercially available; Algorithm cleared for LVEF detection.
The approval was based on data from the pivotal phase 3 PRISMA-3 study that included adults with acute exacerbation of schizophrenia.
The approval was based on data from a phase 3 study that included approximately 400 adults with a history of bipolar I disorder who had a current episode of mania.
Reduced risk for depression, anxiety, or stress-related disorders seen in association with high levels of high-density lipoprotein.
The FDA clearance was based on data from the multicenter, remote, double-blinded, randomized, controlled Mirai study.
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of March. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
Risk for cardiomyopathy increased with duration of treatment for adults aged 20 to 40 years with ADHD
A special United Nations report in 2013 concluded that the Rotenberg Center’s use of the shock devices on students constitutes a violation of the UN convention against torture.
